Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The large percentage of adults with major depressive disorder (MDD) insufficiently responding and/or tolerating conventional monoamine-based antidepressants invites the need for mechanistically novel treatments. Convergent evidence implicates glutamatergic signaling as a potential therapeutic target in MDD. AREAS COVERED: The synthesis herein of preclinical and clinical studies indicates that dextromethorphan (DXM) is well tolerated and exhibits clinically significant antidepressant effects; DXM combined with bupropion has demonstrated replicated and relatively rapid onset efficacy in adults with MDD. DXM efficacy has been preliminarily reported in adults with bipolar depression. The combination of DXM and bupropion represents a pharmacokinetic and pharmacodynamic synergy which may account for the rapidity of action in MDD. EXPERT OPINION: The combination of DXM and bupropion is a safe, well tolerated and efficacious treatment option in adults with MDD. Priority questions are whether DXM/bupropion is uniquely effective across discrete domains of psychopathology (e.g. anhedonia, reward processing, general cognitive systems) and/or whether it is able to significantly improve patient-reported outcomes (e.g. quality of life, psychosocial functioning). The availability of ketamine/esketamine and DXM/bupropion instantiates the relevance of glutamate as a treatment target in MDD. Studies in bipolar depression with DXM/bupropion are warranted as well as in MDD with suicidality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Self-citationThe Forced Swim Test as a Model of Depressive-like Behavior
Yankelevitch-Yahav, R., Franko, M., Huly, A., & Doron, R. (2015) · Journal of Visualized Experiments · doi:10.3791/52587 · Cited by 754
Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671
Zhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390 · cited 2×
“The upregulation of AMPA receptor activity was implicated in the mechanisms of many other existing antidepressant agents [74,75].”
BackgroundResultSlavich, G. M., & Sacher, J. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05326-9 · Cited by 383 · cited 1×
“In addition, a highly replicated finding is that females have a greater susceptibility to experiencing depression and anxiety symptoms [62,63].”
BackgroundHashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
Lam, R. W., McIntosh, D., Wang, J., Enns, M. W., Kolivakis, T., Michalak, E. E., Sareen, J., Song, W.-Y., Kennedy, S. H., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659416 · Cited by 288
Research works printed but not linked: 65
- GBD 2017, 2018, Lancet, 392, 1789, 10.1016/S0140-6736(18)32279-7 · DOI · Paper page
- 10.1016/S0140-6736(20)30925-9 · DOI · Paper page
- 10.1016/j.psc.2018.04.001 · DOI · Paper page
- 10.1586/ern.09.137 · DOI · Paper page
- 10.1126/science.1260781 · DOI · Paper page
- 10.1002/hup.1005 · DOI · Paper page
- 10.3109/15622975.2013.765593 · DOI · Paper page
- 10.1016/S0014-2999(99)00800-6 · DOI
- 10.1093/ijnp/pyaa054 · DOI
- 10.4088/JCP.18r12475 · DOI
- 10.1016/j.pharmthera.2016.04.010 · DOI · Paper page
- 10.1016/j.jad.2014.05.050 · DOI
- 10.1097/WNR.0000000000000646 · DOI
- 10.1016/j.biopha.2016.11.073 · DOI
- 10.1016/j.pbb.2017.09.005 · DOI
- 10.1016/j.pbb.2020.173003 · DOI
- Mesripour A, 2019, Thai J Pharm Sci, 43
- 10.1007/s00221-015-4290-0 · DOI
- Ijomone OM, 2019, Basic Clin Neurosci, 10, 393
- 10.1016/S0006-3223(02)01405-1 · DOI · Paper page
- 10.1016/j.pbb.2006.06.005 · DOI · Paper page
- Can A, 2012, J Vis Exp, e3769
- 10.1016/S0278-5846(01)00324-4 · DOI · Paper page
- 10.1007/978-1-4939-8994-2_10 · DOI · Paper page
- 10.1002/9780470942390.mo150068 · DOI
- Lauterbach EC, 2016, Psychopharmacol Bull, 46, 53
- Messias E, 2012, Prim Care Companion CNS Disord, 14
- 10.1186/s40345-019-0174-8 · DOI
- 10.1016/j.euroneuro.2019.09.585 · DOI
- 10.1097/JCP.0000000000000633 · DOI
- 10.1016/j.euroneuro.2020.09.249 · doi:10.1016/j.euroneuro.2020.09.249
- 10.1016/S0140-6736(20)31544-0 · DOI · Paper page
- 10.1016/j.euroneuro.2014.09.001 · DOI
- 10.1007/s12264-010-0323-7 · DOI · Paper page
- 10.1007/s002130051131 · DOI
- 10.1016/j.neubiorev.2005.03.017 · DOI · Paper page
- Martinak B, 2017, Psychopharmacol Bull, 47, 59
- 10.1097/WNF.0000000000000403 · DOI
- 10.1080/00207454.2018.1545771 · DOI
- 10.1016/j.bbi.2019.04.035 · DOI
- 10.1016/j.bbi.2019.04.032 · DOI · Paper page
- 10.1111/j.1742-7843.2009.00516.x · DOI · Paper page
- 10.1038/sj.mp.4001118 · DOI
- 10.4088/JCP.15com09904 · DOI
- 10.1523/JNEUROSCI.18-07-02697.1998 · DOI · Paper page
- 10.1034/j.1399-5618.2001.30604.x · DOI · Paper page
- 10.1016/j.pharmthera.2010.04.003 · DOI · Paper page
- 10.1097/00008877-200211000-00003 · DOI · Paper page
- 10.1016/j.euroneuro.2007.02.007 · DOI
- 10.1017/S1461145708008547 · DOI · Paper page
- 10.1016/j.bbr.2008.11.036 · DOI · Paper page
- 10.1016/j.neuint.2007.01.008 · DOI
- 10.1038/sj.bjp.0705998 · DOI · Paper page
- 10.1016/j.neuint.2011.07.013 · DOI
- 10.1007/s00213-013-3153-2 · DOI · Paper page
- 10.1016/j.mehy.2012.02.012 · DOI
- 10.1016/j.pneurobio.2015.12.001 · DOI · Paper page
- 10.1016/j.pnpbp.2015.02.015 · DOI
- 10.1016/0006-8993(94)90771-4 · DOI
- 10.1016/S0165-0173(00)00018-7 · DOI · Paper page
- 10.1016/S0166-4328(02)00312-1 · DOI
- 10.1016/j.neulet.2015.12.006 · DOI
- Feighner JP, 1999, J Clin Psychiatry, 60, 4
- 10.4088/JCP.13097tx3c · DOI · Paper page
- 10.1111/ajad.13114 · DOI
Cited by
Novel and emerging treatments for major depression
Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A. H., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 588
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Self-citationClinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
Akbar, D., Rhee, T. G., Ceban, F., Ho, R., Teopiz, K. M., Cao, B., Subramaniapillai, M., Kwan, A. T. H., Rosenblat, J. D., & McIntyre, R. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01032-5 · Cited by 38
Self-citationAll roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Metadata
- Authors
- Majeed, A., Xiong, J., Teopiz, K. M., Ng, J., Ho, R., Rosenblat, J. D., Phan, L., Cao, B., & McIntyre, R. S.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2021-01-02
- Volume
- 26
- Issue
- 1
- Pages
- 63-74
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W3134298422
- Cited by
- 48
- References
- 22
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. https://app.cochat.ai/papers/10.1080/14728214.2021.1898588
- The paper
- Majeed, A., Xiong, J., Teopiz, K. M., Ng, J., Ho, R., Rosenblat, J. D., Phan, L., Cao, B., & McIntyre, R. S. (2021). Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opinion on Emerging Drugs. https://doi.org/10.1080/14728214.2021.1898588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.